| 24.745 -0.255 (-1.02%) | 08-19 10:44 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.09 | 1-year : | 36.31 |
| Resists | First : | 26.62 | Second : | 31.09 |
| Pivot price | 23.76 |
|||
| Supports | First : | 23.35 | Second : | 21.34 |
| MAs | MA(5) : | 24.64 |
MA(20) : | 23.69 |
| MA(100) : | 21.98 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 83.6 |
| RSI | RSI(14): 53 |
|||
| 52-week | High : | 34.18 | Low : | 14.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AKTS ] has closed below upper band by 23.8%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.07 - 25.25 | 25.25 - 25.39 |
| Low: | 23.95 - 24.14 | 24.14 - 24.28 |
| Close: | 24.75 - 25.05 | 25.05 - 25.27 |
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Wed, 19 Aug 2026
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Mon, 17 Aug 2026
Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established Range - Synthetic Long - Vinanet
Fri, 14 Aug 2026
Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com
Fri, 14 Aug 2026
AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Thu, 13 Aug 2026
Aktis: Q2 Earnings Snapshot - WKYC
Thu, 13 Aug 2026
AKTS: Collaboration revenue doubled, R&D spending rose, and cash reserves support operations into 2029 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 14.1 (%) |
| Held by Institutions | 75 (%) |
| Shares Short | 3,740 (K) |
| Shares Short P.Month | 2,910 (K) |
| EPS | -1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.15 |
| Profit Margin | 0 % |
| Operating Margin | -703.7 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 123 % |
| Gross Profit (p.s.) | -1.19 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -20.48 |
| PEG Ratio | 0 |
| Price to Book value | 2.7 |
| Price to Sales | 159.81 |
| Price to Cash Flow | -18.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|